NUCHEV PTY LIMITED (NUC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NUC

NUC - NUCHEV PTY LIMITED

FNArena Sector : Dairy
Year End: June
GICS Industry Group : Food, Beverage & Tobacco
Debt/EBITDA: -0.05
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.195

26 Mar
2025

0.000

OPEN

$0.20

0.000

HIGH

$0.20

0

LOW

$0.20

OTHER COMPANIES IN THE SAME SECTOR
A2M . BFC . BGA . BUB . FSF . SM1 . TFL .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-8.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx11.3 M
Book Value Per Share xxxxxxxxxxxxxxx10.1
Net Operating Cash Flow xxxxxxxxxxxxxxx-3.7 M
Net Profit Margin xxxxxxxxxxxxxxx-64.49 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-53.07 %
Return on Invested Capital xxxxxxxxxxxxxxx-52.18 %
Return on Assets xxxxxxxxxxxxxxx-41.31 %
Return on Equity xxxxxxxxxxxxxxx-53.07 %
Return on Total Capital xxxxxxxxxxxxxxx-45.85 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-3.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx4 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx8 M
Price To Book Value xxxxxxxxxxxxxxx1.29

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.09 %
Cost of Goods Sold xxxxxxxxxxxxxxx12 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

06/03/2025

3

Market Weight

$0.14

-28.21%

Nuchev Pty first-half FY25 result showed a significant improvement in earnings (EBITDA), though sales were below expectations, Wilsons explains.

Revenue grew to $11.1m, driven by a $4.8m contribution from the bWellness acquisition, while Oli6 sales declined -6% due to a prior-year pipeline fill.

Earnings (EBITDA) loss improved to -$1.3m from -$3.2m, benefiting from higher margins and cost efficiencies. Net cash declined to $5.0m from $7.6m.

The analyst lowers sales growth forecast by -8 to 18% but raises gross margin expectations, leading to improved earnings (EBITDA) forecasts.

Target price is cut to 14c from 16c, reflecting a lower valuation multiple. Market Weight rating maintained.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.20 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.40 cents.

NUC STOCK CHART